This week, PerkinElmer launched its BioXpression biomarker platform, which "can speed the discovery of biomarkers" through its biomarker sample-enrichment technology and "highly accurate" mass pattern recognition approach, the company said this week in a statement. The BioXpression platform uses the company's proteomic signature technology that "delivers high throughput and ultra-high mass accuracy and stability, resulting in comprehensive and high-confidence" proteomic signatures, the company said
Cepheid this week introduced its Customer Specified Reagents program, which uses the company's SmartBead technology customer-developed reagents are processed at by Cepheid using its bead technology, the company said in a statement this week. Customer Specified Reagents in the SmartBead format "provide customers with standardized reagents demonstrating enhanced stability, improved reproducibility, and greater efficiency," the company said.
Biotage last week launched its PyroMark Oncology Series genetic tests for genotyping specific cancer mutations and epigenetic phenomena, the company said last week in a statement. The four new tests analyze mutations in the KRAS gene, which is implicated in sporadic colorectal, pancreatic and lung cancers, and the BRAF gene, which is associated with malignant melanoma, papillary thyroid cancer and lung cancer, Biotage said. Additionally, the product quantifies the methylation status of the genes MLH1 and p16, which are hypermethylated in many tumors.